TY - JOUR
T1 - Treatment of allergic rhinitis can improve blood pressure control
AU - Magen, E.
AU - Yosefy, C.
AU - Viskoper, R. J.
AU - Mishal, J.
PY - 2006/11/1
Y1 - 2006/11/1
N2 - Owing to high prevalence of arterial hypertension (AH) and allergic rhinitis (AR), these diseases frequently coexist. The study aimed to assess whether improvement of AR by conventional treatment can improve blood pressure (BP) control in this population. Sixty-eight subjects of both sexes aged 35-60 years with AR and AH were randomized into two groups to receive in addition to their antihypertensive medications: treatment group (n=34) Fluticasone nasal 50μg/spray b.i.d. and Fenoxifenadine 180mg tablets q.d., and control group (n=34) 0.9% NaCl nasal drops b.i.d. Office BP and AR severity (using the Relative Quality of Life Questionnaire (RQLQ)) and high-sensitive C-reactive protein (hs-CRP) were measured at study entry and after 8 weeks in both groups, without changing of antihypertensive medications. In Treatment group an improvement in RQLQ, significant reduction of systolic BP (SBP) (DSBP 7.4±4.3mmHg, P=0.006) and reduction of hs-CRP level (DCRP 2.05±1.08; P=0.028) were observed, whereas diastolic BP (DBP) remained unchanged (DDBP 0.9±1.7mmHg, P=0.7). There was a significant correlation between DRQLQ and DSBP (r=0.86; P=0.019) and between DCRP and DSBP (r=0.56; P=0.027). No statistically significant changes of RQLQ, BP and CRP were observed in the control group. In patients with coincidence of AH and AR, medications meant to improve AR attenuate low-grade systemic inflammation and can lower SBP, but not DBP.
AB - Owing to high prevalence of arterial hypertension (AH) and allergic rhinitis (AR), these diseases frequently coexist. The study aimed to assess whether improvement of AR by conventional treatment can improve blood pressure (BP) control in this population. Sixty-eight subjects of both sexes aged 35-60 years with AR and AH were randomized into two groups to receive in addition to their antihypertensive medications: treatment group (n=34) Fluticasone nasal 50μg/spray b.i.d. and Fenoxifenadine 180mg tablets q.d., and control group (n=34) 0.9% NaCl nasal drops b.i.d. Office BP and AR severity (using the Relative Quality of Life Questionnaire (RQLQ)) and high-sensitive C-reactive protein (hs-CRP) were measured at study entry and after 8 weeks in both groups, without changing of antihypertensive medications. In Treatment group an improvement in RQLQ, significant reduction of systolic BP (SBP) (DSBP 7.4±4.3mmHg, P=0.006) and reduction of hs-CRP level (DCRP 2.05±1.08; P=0.028) were observed, whereas diastolic BP (DBP) remained unchanged (DDBP 0.9±1.7mmHg, P=0.7). There was a significant correlation between DRQLQ and DSBP (r=0.86; P=0.019) and between DCRP and DSBP (r=0.56; P=0.027). No statistically significant changes of RQLQ, BP and CRP were observed in the control group. In patients with coincidence of AH and AR, medications meant to improve AR attenuate low-grade systemic inflammation and can lower SBP, but not DBP.
UR - http://www.scopus.com/inward/record.url?scp=33750320603&partnerID=8YFLogxK
U2 - 10.1038/sj.jhh.1002088
DO - 10.1038/sj.jhh.1002088
M3 - Article
C2 - 16967045
AN - SCOPUS:33750320603
SN - 0950-9240
VL - 20
SP - 888
EP - 893
JO - Journal of Human Hypertension
JF - Journal of Human Hypertension
IS - 11
ER -